1. One-year visual outcome of secondary piggyback pinhole device implantation in pseudophakic eyes with irregular corneal astigmatism and iris trauma
- Author
-
Mohamed Elalfy, Vivian W. M. Ho, Damian Lake, and Samer Hamada
- Subjects
Adult ,medicine.medical_specialty ,genetic structures ,Corneal diseases ,Iris ,Spherical equivalent ,Refraction, Ocular ,Article ,03 medical and health sciences ,Eye Injuries ,0302 clinical medicine ,Lens Implantation, Intraocular ,Ophthalmology ,medicine ,Humans ,Manifest refraction ,Eye manifestations ,Iris (anatomy) ,Aged ,Retrospective Studies ,Aged, 80 and over ,Eye, Artificial ,business.industry ,Astigmatism ,Glare (vision) ,Mean age ,Middle Aged ,eye diseases ,Treatment Outcome ,medicine.anatomical_structure ,030221 ophthalmology & optometry ,Pinhole (optics) ,Implant ,business ,Corneal astigmatism ,030217 neurology & neurosurgery - Abstract
Purpose Retrospective case series evaluating the efficacy and safety of implanting XtraFocus™ pinhole device in pseudophakic patients with irregular corneal astigmatism with concurrent or standalone iris defect. Methods Electronic case records were searched for: uncorrected distance visual acuities (UDVA) and corrected distance visual acuities (CDVA), automatic or manifest refraction and spherical equivalent (SE). All main outcomes were evaluated preoperatively and postoperatively at 1, 3, 6, 9 and 12 months, along with patients’ satisfactory outcome and complications. Results Eleven pseudophakic eyes of 11 patients with a mean age of 54 (range 27–81) years were included. Median UDVA improved significantly from logMAR 0.7 (range 0.1–1.22) pre-operatively to 0.4 (range 0–1.3) at 1-month (p = 0.002); median CDVA remained unchanged at logMAR 0.4 (range 0–0.1) pre-operatively and 0.4 (range 0–0.8) at 1-month (p = 0.36). There were no significant statistical differences in both UDVA and CDVA between the post-operative periods. Ten patients (90.9%) had initial UDVA improvement at 1-month post op. Eight (72.7%) patients expressed satisfaction with improved vision or reduction of glare/halos. Three (27.3%) patients had unsatisfactory visual outcome resulting in 2 requested for implant explantation due to worsening of glare and distressing floaters. Conclusions XtraFocus™ is effective in improving vision or reducing glare in pseudophakic patients with irregular corneal astigmatism or intragenic iris trauma, with over 70% expressed satisfactory outcome. Disturbing floaters and glare preclude its use in some resulting in implant explantation.
- Published
- 2021
- Full Text
- View/download PDF